Odyssey Ventures leads $5m investment in MintNeuro, the chip platform for neural devices and brain-computer interfaces
Odyssey Ventures backs the Imperial College London spinout as it moves from working silicon to commercial scale-up and expands into the US
London, UK, 7 October 2026: Odyssey Ventures, the venture platform backing the UK and Europe's most ambitious AI and deep tech founders and scaling them in the US from day one, today announced that it has led a $5 million investment round in MintNeuro, a semiconductor company building specialised chips for neural devices, from implants to wearables. The round includes participation from 33East, JSK Investments and Alumni Ventures, with returning investment from Empirical Ventures, Jumpspace Ventures and early investors.
MintNeuro's chips give neural device developers better performance than generic components, with less risk, lower cost and a faster route to market than custom chip design. The funding will accelerate product launch, expand delivery of pre-release silicon to partners and build the company's US presence alongside its UK and European base.
The chip gap holding back neurotechnology
Neural devices are opening new ways to understand and treat conditions across neurology, mental health and beyond, from Parkinson's disease, epilepsy and depression to hearing loss and inflammatory disease. They include brain-computer interfaces (BCIs), neuromodulation systems, sensory prostheses and bioelectronic medicines.
Progress across the industry has been held back by the lack of standard chips designed for the extreme power, size, safety and signal-quality demands of these devices. Developers have had to choose between adapting generic components never designed for the body, or funding years of custom chip development.
MintNeuro closes that gap with a modular semiconductor platform purpose-built for neural sensing, signal processing and stimulation: listening to the body's nerve signals, interpreting them and delivering precise electrical pulses to treat disease or restore function. Its building blocks combine these functions efficiently at system level, supporting more integrated, closed-loop interfaces with the nervous system. Developers can build smaller, lower-power devices and move from research to clinical use sooner.
Working silicon and commercial traction
MintNeuro has already delivered working silicon and reached key integration milestones with research and development partners including Motif Neurotech and Amber Therapeutics. Earlier this year it signed a partnership and multi-year commercial chip supply agreement with Motif, supporting development of Motif's minimally invasive neurostimulator, initially targeting treatment-resistant depression. A growing number of neural device companies and implant research teams are now evaluating or integrating its technology.
MintNeuro will use the new capital to grow its engineering and commercial teams, bring its products to market, support customers as they adopt its chips and strengthen its presence in the US.
Michelle Robson, Founding Partner at Odyssey Ventures, said: "Neural devices such as BCIs represent one of the most exciting frontier technology opportunities today, and significant value will accrue to those solving the foundational infrastructure challenges that stand between innovation and widespread adoption. MintNeuro has the technology, market pull and ambition to become a globally important semiconductor company, and we are backing this exceptional team as it scales from the UK into global markets, including Silicon Valley."
Dorian Haci, Co-Founder and CEO of MintNeuro, said: "Every neural device depends on the chips inside it. Today, most device and therapy developers still have to choose between generic components that were never designed for the body and years of custom chip development. We are building the chips that end that trade-off. This funding moves us from technology validation to commercial scale-up, with more customer programmes, faster product launches and our chips in the hands of many more developers. Our ambition is clear: to make MintNeuro the semiconductor platform the global neurotechnology industry builds on."
Professor Tim Denison, Chair of MintNeuro, added: "Neurotechnology is entering a phase where specialised hardware will determine how far, and how fast, the field can go. MintNeuro's semiconductor technology is well-placed to remove the key obstacle to industry scale, which could dramatically accelerate the pace of innovation."
– Ends –
Notes to editors
About Odyssey Ventures
Odyssey Ventures invests in the UK and Europe's most ambitious AI and deep tech founders and helps them go to the US for capital, customers and talent to scale. Its early-stage Discovery funds invest at Pre-Seed and Seed, with follow-on investment through the Access growth platform.
About MintNeuro (www.mintneuro.com)
Founded as a spinout from Imperial College London, MintNeuro is building the semiconductor foundation for the next generation of neurotechnology. The company develops specialised chips that enable devices to connect with the brain and nervous system, helping innovators create new therapies for neurological and mental health conditions. Its immediate focus is medical applications, where size, power, reliability and safety are critical, with a long-term vision to become the industry-standard semiconductor platform for brain-computer interfaces, bioelectronic medicine and other technologies that connect humans and machines.
Press contacts
Odyssey Ventures: Izzy Fox, izzy@odyssey.ventures
MintNeuro: EvokedSet PR, nicky@evokedset.com